The weekly litigation news digest is live. Subscribe now

IP Verse

Apixaban Formulations - EP3017811

The patent EP3017811 was granted to Bristol Myers Squibb on Dec 5, 2018. The application was filed on Feb 24, 2011 under application number EP15190823A. The patent is currently recorded with a legal status of "Revoked".

EP3017811

BRISTOL MYERS SQUIBB
Application Number
EP15190823A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Publication Date
Dec 5, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Tablets containing apixaban for treating thromboembolic disorders with improved bioavailability by using apixaban particles with a maximum size cutoff of less than 89 microns. The tablets are made by a dry granulation process that produces apixaban particles with a d90 size below 89 microns. This allows consistent in vivo dissolution and exposure compared to larger particles. The smaller particle size improves absorption and therapeutic efficacy compared to tablets with larger particles made by wet granulation or using large apixaban particles.

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
STADA ARZNEIMITTELSep 5, 2019KERNEBECKADMISSIBLE
GENERICS UKSep 4, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
ZENTIVASep 4, 2019HOFFMANN EITLEADMISSIBLE
INTAS PHARMACEUTICALSSep 4, 2019ACCORD HEALTHCAREWITHDRAWN
POLPHARMASep 3, 2019ELKINGTON AND FIFEADMISSIBLE
KRKASep 3, 2019HOEFER & PARTNER PATENTANWALTE MBBWITHDRAWN
HAMM & WITTKOPPAug 30, 2019HAMM & WITTKOPPADMISSIBLE
SANDOZAug 29, 2019KRAUS & LEDERERADMISSIBLE
SANDOZAug 29, 2019KRAUS & LEDERER PARTGMBBADMISSIBLE
TEVA PHARMACEUTICALSAug 27, 2019D YOUNGADMISSIBLE

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2006069258
DESCRIPTIONUS6967208
EXAMINATIONWO2011106478
OPPOSITIONEP2538925
OPPOSITIONUS2006069258
OPPOSITIONUS2006160841
OPPOSITIONUS2007259913
OPPOSITIONUS2009291913
OPPOSITIONUS6967208
OPPOSITIONUS7396932
OPPOSITIONWO2006108643
OPPOSITIONWO2007001385
OPPOSITIONWO2007022165
OPPOSITIONWO2008031782
OPPOSITIONWO2009135947
OPPOSITIONWO2010003811
OPPOSITIONWO2010147978
OPPOSITIONWO2011106478
SEARCHUS2006160841
SEARCHWO2007022165
SEARCHWO2009135947
SEARCHWO2010147978

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents